Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.
HVTN 702 is but one of many vaccine trials underway, researchers note.
Teaching young people of all ages about HIV is essential. But how do you start to outline a class?
Health care providers and educators need to acknowledge the impact of clinical bias and reframe sexual health education when it comes to tending to cisgender women's needs, Chase Alston writes.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.
While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
This may be a temporary setback, but long-acting antiretroviral therapy is still on the way, experts say.
Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.